Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$... (in Singapore. Companies such as GlaxoSmi...)

HOME >> MEDICINE >> NEWS

Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion

Date:6/18/2008

in Singapore. Companies such as GlaxoSmithKline and Schering-Plough have also expanded beyond manufacturing into process development to support and strengthen their production base. We will continue to aggressively build up new capabilities to support the anticipated strong growth in this sector."

Mr. Gaetan Angoh, Managing Director for Schering-Plough LTD (Singapore branch), said: "As a pioneer US pharma investor since 1995, Schering-Plough has leveraged on Singapore's solid infrastructure, skilled workforce and pro- business environment to expand to our current manufacturing campus. Today, we are one of the largest employers in Singapore's biomedical sciences industry with over 800 people."

In addition to chemical-based pharmaceuticals, Singapore has also built up an impressive track record in biologics manufacturing. Within less than two years, Genentech, GlaxoSmithKline, Lonza and Novartis announced their decisions to site a total of five major biologics manufacturing facilities amounting to US$1.5 billion in Singapore. The Singapore EDB, in partnership with the industry, has put in place a comprehensive range of programs to develop manpower and technological capabilities in support of biologics manufacturing.

Note 1: Abbott, Genentech, GSK, Lonza, MSD, SD, Novartis, Pfizer,

sanofi-aventis, Schering-Plough, Wyeth, Alcon

Reliable Skilled Manpower

Industry players in Singapore also work closely together to expand the talent pool to support the growth of the industry. In addition to joint campaigns to promote careers in the pharmaceutical and biotechnology industry, the companies lead industry-wide initiatives to upgrade the existing workforce and attract new entrants from other industries.

The Singapore Academy of GxP Excellence (SAGE) is one particularly noteworthy initiative. Launched by the National University of Singapore (NUS) in March 2008, the Academy works closely with industry representatives
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Lab-on-chip testing for bird flu developed by Singapore scientists
2. Hill-Rom Announces Singapore Will Be Site for Asia-Pacific Innovation Center
3. Three Hospitals in Singapore Join Companion Global Healthcare Network
4. Wyeth to Expand State-of-the-Art Nutritional Manufacturing Facility in Singapore
5. Hospital Care in Singapore Now Available to American Patients at Pre-Negotiated, In-Network Rates Far Lower than Comparable Services in the U.S.
6. Marian Koshland Science Museum forms partnership with Science Center Singapore
7. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
8. Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research
9. Health Information Exchange Consensus Conference Reinforces Key Role of State-Level Entities
10. Pilot study reinforces use of portable anteroom HEPA filtration
11. AMA Reinforces Commitment to Cover the Uninsured at Annual Meeting

Post Your Comments:

Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$...(in Singapore. Companies such as GlaxoSmi...),Health